Ad Scientiam officially establishes presence in the United States

We are thrilled to announce a decisive step in our international development: the opening of our American subsidiary and the registration of MSCopilot® with the FDA (510(k) exemption).

This milestone follows the success of the MS-FLOWER pilot, conducted in partnership with Sanofi across 4 major US MS centers (Austin, St. Louis, Oklahoma City, New Orleans) — 62 patients enrolled, with the goal of integrating MSCopilot® into standard care pathways. Initial results from the MS-FLOWER pilot will be presented at AAN 2026.

By establishing ourselves in the United States, we will:

Accelerate patient impact: Bring our clinically validated digital monitoring solution to millions of MS patients in the United States.

Drive innovation: Collaborate closely with global MedTech leaders, clinical centers, and research institutes.

Ensure excellence: Affirm our commitment to the most demanding regulatory standards for digital biomarkers.

Today we are building a bridge between digital innovation and clinical excellence. Huge congratulations to the entire Ad Scientiam team for making this project possible!